Country eligibility info - Horizon Europe

Benin - Third Countries automatically eligible for funding
Please note that this information sheet will be updated regularly and the list of countries divided into the different categories can always change over the period of Horizon Europe. If you are involving a partner from a non-EU country in your consortium please always check the status of this country in Horizon Europe at the moment of submission in the Horizon Europe Programme Guide.

Benin belongs to the group of Third Countries automatically eligible for funding

Funding possible - Scroll further to find out what this means exactly

Specific remarks for Benin

No extra info available

Eligibility for Third Countries automatically eligible for funding means...

Short explanation

Most Horizon Europe calls are open to participants from non-EU countries, also called Third Countries. But funding is only automatically available if they are associated or if they appear in the list of Low and Middle Income Countries as listed in the Horizon Europe Programme Guide

Specific third countries can also be excluded from participation to the programme or to a part of the programme  and/or to specific call topics mainly in order to safeguard the EU’s strategic assets, interests, autonomy or security. 

N/A

All details regarding country eligibility is compiled in the infosheet “International cooperation".

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.